Nele De Meulenaere

Nele De Meulenaere

Auto-generated profile, based on publicly available information

Nele De Meulenaere

Center of Medical Genetics University of Antwerp and Antwerp University Hospital Edegem Belgium

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
14 November 2025 in Molecular Oncology
Verified
Journal Article
Open access
JVJanah Vandenhoeck
Janah Vandenhoeck
NMNele De Meulenaere
Nele De Meulenaere
TVThomas Vanpoucke
Thomas Vanpoucke
JIJoe Ibrahim
Joe Ibrahim
DPDieter Peeters
Dieter Peeters
KBKen Op de Beeck
Ken Op de Beeck
Pleural mesothelioma (PM) is a rare and aggressive cancer that often requires multiple diagnostic procedures before a definitive diagnosis can be made. To improve diagnostic accuracy, we developed a DNA methylation‐based biomarker assay capable of distinguishing PM from healthy pleura and other pleural pathologies. Using Infinium EPIC array data, we identified 744 hypermethylated CpG sites in PM as candidate biomarkers. These were validated in silico using external datasets, yielding a high mean AUC of 0.935. Clinical validation was performed using IMPRESS, a novel bisulfite‐free methylation detection technique that enables simultaneous analysis of thousands of CpG sites. A two‐step classifier approach was applied: the first model differentiated tumoral from nontumoral pleura with 89.2% sensitivity and 93.5% specificity, while the second model distinguished PM from pleural metastases with 85.2% sensitivity and 100% specificity. These results demonstrate that our methylation‐based biomarker panel offers a highly accurate and minimally invasive tool for differentiating PM from other pleural conditions, potentially streamlining the diagnostic process and improving clinical decision‐making.